Neumora Therapeutics, Inc. (NMRA) shareholders
NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.47+0.01 (+1.37%)
Close on Nov 11, 2026Market cap $88.87MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
40.4%
76M of 188M shares
Institutional holders
113
28 new, 28 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
0 buys · 15 sales
Net sold $784.12K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kristina Burow Joint filing with ARCH Venture Fund VII, L.P. (18.60%), ARCH Venture Fund VIII Overage, L.P. (18.60%) and 14 more | 33,965,419 | 18.70% | 13D (active) amendment | Mar 30, 2026 |
| Anup Arora Joint filing with K2 HealthVentures Equity Trust LLC (6.60%), Parag Shah (6.60%) | 11,397,310 | 6.60% | 13G (passive) | May 9, 2025 |
| K2 HealthVentures Equity Trust LLC Joint filing with Parag Shah (5.01%), Anup Arora (5.01%) | 8,997,035 | 5.01% | 13G (passive) amendment | Dec 31, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (5.40%) | 8,622,468 | 5.40% | 13G (passive) | Jun 28, 2024 |
| Paul L Berns | 8,226,272 | 5.10% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NMRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Siren, L.L.C. | 8,497,822 | 4.52% | $14.45M | – | 0.29% |
| BlackRock, Inc. | 7,791,869 | 4.15% | $13.25M | +5,737,553 | 0.00% |
| Softbank Group Corp. | 6,090,301 | 3.24% | $10.35M | – | 0.06% |
| Vanguard Capital Management LLC | 4,669,585 | 2.49% | $7.94M | +777,692 | 0.00% |
| MIC Capital Management UK LLP | 4,460,700 | 2.37% | $7.58M | – | 1.92% |
| FMR LLC | 3,498,869 | 1.86% | $5.95M | +211 | 0.00% |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | 3,309,123 | 1.76% | $5.63M | – | 0.06% |
| Geode Capital Management, LLC | 2,607,289 | 1.39% | $4.43M | +1,520,424 | 0.00% |
| ICONIQ Capital, LLC | 2,559,090 | 1.36% | $4.35M | – | 0.13% |
| Two Sigma Investments, LP | 2,244,829 | 1.19% | $3.82M | +208,137 | 0.00% |
| Orbimed Advisors LLC | 2,139,882 | 1.14% | $3.64M | New | 0.07% |
| Lunate Capital Ltd | 2,124,143 | 1.13% | $3.61M | – | 1.84% |
| Boxer Capital Management, LLC | 2,000,000 | 1.06% | $3.40M | New | 0.26% |
| Johnson & Johnson | 1,849,445 | 0.98% | $3.14M | – | 0.39% |
| State Street Corp | 1,582,119 | 0.84% | $2.69M | +1,183,400 | 0.00% |
| Tudor Investment Corp Et Al | 1,356,147 | 0.72% | $2.31M | +584,729 | 0.00% |
| Ikarian Capital, LLC | 1,278,408 | 0.68% | $2.17M | – | 0.23% |
| Renaissance Technologies LLC | 1,262,304 | 0.67% | $2.15M | −126,694 | 0.00% |
| Affinity Asset Advisors, LLC | 1,070,651 | 0.57% | $1.82M | New | 0.08% |
| Marshall Wace, Llp | 904,458 | 0.48% | $1.54M | −290,852 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 113 | 76M | 40.4% | 28 / 37 | 23 / 28 | 21M | 15M |
| Q1 2026 | 114 | 70M | 37.5% | 24 / 34 | 32 / 10 | 20M | 8M |
| Q4 2025 | 102 | 63M | 33.6% | 24 / 34 | 21 / 12 | 16M | 3M |
| Q3 2025 | 93 | 51M | 27.0% | 13 / 15 | 41 / 18 | 3M | 8M |
| Q2 2025 | 98 | 56M | 29.8% | 24 / 28 | 28 / 40 | 6M | 15M |
| Q1 2025 | 115 | 65M | 34.7% | 33 / 32 | 29 / 50 | 14M | 26M |
| Q4 2024 | 134 | 80M | 42.8% | 44 / 39 | 31 / 14 | 19M | 7M |
| Q3 2024 | 104 | 69M | 36.6% | 23 / 34 | 23 / 11 | 16M | 15M |
| Q2 2024 | 93 | 73M | 38.6% | 24 / 43 | 13 / 19 | 24M | 4M |
| Q1 2024 | 88 | 53M | 28.2% | 37 / 17 | 18 / 9 | 13M | 3M |
| Q4 2023 | 60 | 44M | 23.3% | 34 / 9 | 9 / 12 | 9M | 10M |
| Q3 2023 | 38 | 44M | 23.4% | 38 / 0 | 0 / 0 | 44M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
75 funds held NMRA in Q2 2026, 77% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NMRA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,435,554 | 1.83% | $5.84M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,504,450 | 1.33% | $4.26M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,126,060 | 0.60% | $1.91M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,116,548 | 0.59% | $1.80M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 872,018 | 0.46% | $1.48M | 0.01% | Jun 30, 2026 |
| iShares Biotechnology ETF | 543,567 | 0.29% | $924.06K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 465,376 | 0.25% | $860.95K | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 415,640 | 0.22% | $768.93K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 344,428 | 0.18% | $585.53K | 0.04% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 250,075 | 0.13% | $402.62K | 0.01% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 225,000 | 0.12% | $382.50K | 0.26% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 221,105 | 0.12% | $355.98K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 191,821 | 0.10% | $326.10K | 0.01% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 179,998 | 0.10% | $333.00K | 0.00% | May 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 177,346 | 0.09% | $285.53K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul L. Berns | See Remarks, Director | 7,528,282 | 4.01% | Aug 21, 2026 |
| Joshua Pinto | President & CEO, Director | 209,950 | 0.11% | Aug 21, 2026 |
| Jason Duncan | See Remarks | – | – | Aug 21, 2026 |
| Daljit Singh Aurora | See Remarks | 91,490 | 0.05% | Aug 21, 2026 |
| Michael Lee Milligan | See Remarks | 21,034 | 0.01% | Aug 21, 2026 |
| Robert A. Lenz | Head of R&D | 309,092 | 0.16% | Feb 20, 2025 |
| Alaa Halawa | Director | 20,100 | 0.01% | May 29, 2026 |
| Matthew K. Fust | Director | 20,100 | 0.01% | May 29, 2026 |
| Kristina Burow | Director, 10% owner | 33,895,555 | 18.04% | May 29, 2026 |
| David Piacquad | Director | 20,100 | 0.01% | May 29, 2026 |
| Maykin Ho | Director | 20,100 | 0.01% | May 29, 2026 |
| Keith Crandell | 10% owner | – | – | Oct 29, 2025 |
| Robert Nelsen | 10% owner | 3,859,898 | 2.05% | Oct 29, 2025 |
| ARCH Venture Partners XII, L.P. | 10% owner | – | – | Oct 29, 2025 |
| Clinton Bybee | 10% owner | – | – | Oct 29, 2025 |
| ARCH Venture Partners VII, L.P. | 10% owner | – | – | Oct 29, 2025 |
| ARCH Venture Partners VII, LLC | 10% owner | 10,620,716 | 5.65% | Oct 29, 2025 |
| ARCH Venture Fund VII, L.P. | 10% owner | – | – | Oct 29, 2025 |
| ARCH Venture Partners XII, LLC | 10% owner | 33,847,838 | 18.01% | Oct 29, 2025 |
| ARCH Venture Fund X Overage, L.P. | 10% owner | – | – | Oct 29, 2025 |
| ARCH Venture Partners VIII, LLC | 10% owner | 33,847,838 | 18.01% | Oct 29, 2025 |
| ARCH Venture Fund VIII Overage, L.P. | 10% owner | – | – | Oct 29, 2025 |
| ARCH Venture Partners X, L.P. | 10% owner | 31,932,138 | 16.99% | Oct 29, 2025 |
| ARCH Venture Fund X, L.P. | 10% owner | – | – | Oct 29, 2025 |
| ARCH Venture Fund XII, L.P. | 10% owner | 4,131,207 | 2.20% | Oct 29, 2025 |
| ARCH Venture Partners X Overage, L.P. | 10% owner | – | – | Oct 29, 2025 |
| ARCH Venture Partners X, LLC | 10% owner | – | – | Oct 29, 2025 |
| Steven Gillis | 10% owner | – | – | Oct 29, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Daljit Singh Aurora See Remarks | Aug 21, 2026 | Option exercise | +21,055 | $0.72 | $15.16K | 21,055 |
| Daljit Singh Aurora See Remarks | Aug 21, 2026 | Sale | −21,055 | $1.60 | $33.69K | 0 |
| Daljit Singh Aurora See Remarks | Aug 21, 2026 | Sale | −20,553 | $1.59 | $32.68K | 48,750 |
| Daljit Singh Aurora See Remarks | Aug 21, 2026 | Option exercise | +20,553 | $0.72 | $14.80K | 69,303 |
| Daljit Singh Aurora See Remarks | Aug 20, 2026 | Sale | −67,741 | $1.51 | $102.29K | 48,750 |
| Daljit Singh Aurora See Remarks | Aug 20, 2026 | Option exercise | +21,685 | $0.72 | $15.61K | 21,685 |
| Daljit Singh Aurora See Remarks | Aug 20, 2026 | Option exercise | +45,026 | $0.72 | $32.42K | 66,711 |
| Daljit Singh Aurora See Remarks | Aug 20, 2026 | Sale | −66,711 | $1.51 | $100.73K | 0 |
| Daljit Singh Aurora See Remarks | Aug 20, 2026 | Option exercise | +67,741 | $0.72 | $48.77K | 116,491 |
| Daljit Singh Aurora See Remarks | Aug 19, 2026 | Option exercise | +13,268 | $0.72 | $9.55K | 62,018 |
| Daljit Singh Aurora See Remarks | Aug 19, 2026 | Option exercise | +17,732 | $0.72 | $12.77K | 79,750 |
| Daljit Singh Aurora See Remarks | Aug 19, 2026 | Sale | −31,000 | $1.65 | $51.15K | 48,750 |
| Daljit Singh Aurora See Remarks | Aug 19, 2026 | Option exercise | +30,918 | $0.72 | $22.26K | 30,918 |
| Daljit Singh Aurora See Remarks | Aug 19, 2026 | Sale | −30,918 | $1.65 | $51.01K | 0 |
| Daljit Singh Aurora See Remarks | Aug 18, 2026 | Option exercise | +34,162 | $0.72 | $24.60K | 82,912 |
| Daljit Singh Aurora See Remarks | Aug 18, 2026 | Sale | −34,162 | $1.58 | $53.98K | 48,750 |
| Daljit Singh Aurora See Remarks | Aug 18, 2026 | Option exercise | +34,987 | $0.72 | $25.19K | 34,987 |
| Daljit Singh Aurora See Remarks | Aug 18, 2026 | Sale | −34,987 | $1.59 | $55.63K | 0 |
| Daljit Singh Aurora See Remarks | Aug 17, 2026 | Option exercise | +1 | $0.72 | $1 | 140,440 |
| Daljit Singh Aurora See Remarks | Aug 17, 2026 | Sale | −34,020 | $1.49 | $50.69K | 48,750 |
| Daljit Singh Aurora See Remarks | Aug 17, 2026 | Sale | −57,670 | $1.51 | $87.08K | 82,770 |
| Daljit Singh Aurora See Remarks | Aug 17, 2026 | Option exercise | +1,424 | $0.72 | $1.03K | 140,439 |
| Daljit Singh Aurora See Remarks | Aug 17, 2026 | Option exercise | +25,279 | $0.72 | $18.20K | 25,279 |
| Daljit Singh Aurora See Remarks | Aug 17, 2026 | Option exercise | +29,737 | $0.72 | $21.41K | 55,016 |
| Daljit Singh Aurora See Remarks | Aug 17, 2026 | Sale | −55,016 | $1.50 | $82.52K | 0 |
| Daljit Singh Aurora See Remarks | Aug 17, 2026 | Option exercise | +15,355 | $0.72 | $11.06K | 139,015 |
| Daljit Singh Aurora See Remarks | Aug 17, 2026 | Option exercise | +40,890 | $0.72 | $29.44K | 123,660 |
| Paul L. Berns See Remarks, Director | Feb 17, 2026 | Sale | −9,819 | $3.51 | $34.46K | 7,395,185 |
| Daljit Singh Aurora See Remarks | Feb 17, 2026 | Sale | −6,165 | $3.56 | $21.95K | 82,770 |
| Joshua Pinto President | Feb 17, 2026 | Sale | −5,967 | $3.54 | $21.12K | 57,783 |
| Michael Lee Milligan See Remarks | Feb 17, 2026 | Sale(10b5-1 plan) | −1,436 | $3.57 | $5.13K | 21,034 |
| Daljit Singh Aurora See Remarks | Nov 11, 2025 | Sale(10b5-1 plan) | −114,703 | $2.68 | $307.40K | 0 |
| Kristina Burow Director, 10% owner | Oct 27, 2025 | Buy | +1,915,700 | $2.61 | $5.00M | 6,046,907 |
| ARCH Venture Partners XII, LLC 10% owner | Oct 27, 2025 | Buy | +1,915,700 | $2.61 | $5.00M | 6,046,907 |
| ARCH Venture Partners VIII, LLC 10% owner | Oct 27, 2025 | Buy | +1,915,700 | $2.61 | $5.00M | 6,046,907 |
| Joshua Pinto President | May 21, 2025 | Gift | +13,202 | – | – | 152,167 |
| Joshua Pinto President | May 21, 2025 | Gift | −13,202 | – | – | 63,750 |
| Michael Lee Milligan See Remarks | Feb 18, 2025 | Sale(10b5-1 plan) | −1,978 | $1.69 | $3.34K | 22,470 |
| Daljit Singh Aurora Chief Strategy Officer | Feb 18, 2025 | Sale(10b5-1 plan) | −8,565 | $1.68 | $14.39K | 88,935 |
| Paul L. Berns See Remarks, Director | Feb 18, 2025 | Sale(10b5-1 plan) | −13,871 | $1.69 | $23.44K | 7,405,004 |
| Joshua Pinto President | Feb 18, 2025 | Sale(10b5-1 plan) | −8,048 | $1.67 | $13.44K | 76,952 |
| Robert A. Lenz Head of R&D | Feb 18, 2025 | Sale(10b5-1 plan) | −5,614 | $1.67 | $9.38K | 309,092 |
| Paul L. Berns Director | Dec 27, 2024 | Gift | −133,097 | – | – | 7,551,972 |
| Paul L. Berns Director | Dec 27, 2024 | Gift | −133,097 | – | – | 7,418,875 |
| Paul L. Berns Director | Dec 27, 2024 | Gift | −133,097 | – | – | 7,685,069 |
| Matthew K. Fust Director | Oct 18, 2024 | Sale(10b5-1 plan) | −14,049 | $17.03 | $239.25K | 20,100 |
| Matthew K. Fust Director | Oct 18, 2024 | Option exercise | +7,844 | $2.52 | $19.77K | 34,149 |
| Matthew K. Fust Director | Oct 18, 2024 | Option exercise | +6,205 | $8.79 | $54.54K | 26,305 |
| Matthew K. Fust Director | Oct 17, 2024 | Sale(10b5-1 plan) | −7,739 | $17.01 | $131.64K | 20,100 |
| Matthew K. Fust Director | Oct 17, 2024 | Option exercise | +2,156 | $2.52 | $5.43K | 27,839 |
| Matthew K. Fust Director | Oct 17, 2024 | Option exercise | +1,800 | $8.79 | $15.82K | 25,683 |
| Matthew K. Fust Director | Oct 17, 2024 | Option exercise | +3,783 | $8.32 | $31.47K | 23,883 |
| Robert A. Lenz Head of R&D | Oct 10, 2024 | Sale(10b5-1 plan) | −8,260 | $15.09 | $124.64K | 314,706 |
| Robert A. Lenz Head of R&D | Oct 9, 2024 | Sale(10b5-1 plan) | −5,563 | $15.01 | $83.50K | 322,966 |
| Robert A. Lenz Head of R&D | Sep 18, 2024 | Sale(10b5-1 plan) | −10,676 | $12.09 | $129.07K | 328,529 |
| Robert A. Lenz Head of R&D | Sep 17, 2024 | Sale(10b5-1 plan) | −30,788 | $11.81 | $363.61K | 339,205 |
| Robert A. Lenz Head of R&D | Sep 12, 2024 | Sale(10b5-1 plan) | −32,948 | $11.43 | $376.60K | 369,993 |
| Joshua Pinto Chief Financial Officer | Aug 27, 2024 | Sale(10b5-1 plan) | −15,693 | $11.39 | $178.74K | 138,965 |
| Joshua Pinto Chief Financial Officer | Aug 26, 2024 | Sale(10b5-1 plan) | −31,642 | $11.78 | $372.74K | 154,658 |
| Joshua Pinto Chief Financial Officer | Aug 23, 2024 | Sale(10b5-1 plan) | −24,169 | $11.59 | $280.12K | 186,300 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
4.83%
7M shares short
Days to cover
5.1
At 1M shares a day
Change since last report
+24.2%
From 6M shares
Short volume, 20 days
57.7%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Neumora Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 91,920 shares on Aug 27, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Daljit Singh Aurora Officer | Aug 21, 2026 | 41,608 | $66.38K | Aug 21, 2026 | Exercise of employee stock options |
| Daljit Singh Aurora Officer | Aug 20, 2026 | 134,452 | $203.58K | Aug 20, 2026 | Exercise of employee stock options |
| Daljit Singh Aurora Officer | Aug 19, 2026 | 61,918 | $101.92K | Aug 19, 2026 | Exercise of employee stock options |
| Daljit Singh Aurora Officer | Aug 18, 2026 | 69,149 | $109.62K | Aug 18, 2026 | Exercise of employee stock options |
| Daljit Singh Aurora Officer | Aug 17, 2026 | 146,706 | $220.14K | Aug 17, 2026 | Exercise of employee stock options |
| Michael Lee Milligan Officer | Feb 17, 2026 | 1,436 | $5.12K | Feb 17, 2026 | Vesting of restricted stock unit award |
| Joshua Pinto Officer | Feb 17, 2026 | 5,967 | $21.09K | Feb 17, 2026 | Vesting of restricted stock unit award |
| Daljit Singh Aurora Officer | Feb 17, 2026 | 6,165 | $21.92K | Feb 17, 2026 | Vesting of restricted stock unit award |
| Paul L. Berns Officer | Feb 17, 2026 | 9,819 | $34.46K | Feb 17, 2026 | Vesting of restricted stock unit award |
| Aurora Family Trust Director, Officer | Nov 12, 2025 | 114,703 | $307.03K | Nov 11, 2025 | Stock Bonus |
| Henry O. Gosebruch Officer, Director | Mar 12, 2025 | 15,000 | $21.45K | Mar 12, 2025 | Open Market Purchase |
| Paul L. Berns Officer | Feb 18, 2025 | 13,871 | $23.47K | Feb 18, 2025 | Vesting of restricted stock unit award |
| Henry O. Gosebruch Officer, Director | Feb 18, 2025 | 6,857 | $11.46K | Feb 18, 2025 | Vesting of restricted stock unit award |
| Michael Lee Milligan Officer | Feb 18, 2025 | 1,978 | $3.35K | Feb 18, 2025 | Vesting of restricted stock unit award |
| Joshua Pinto Officer | Feb 18, 2025 | 8,048 | $13.48K | Feb 18, 2025 | Vesting of restricted stock unit award |
See a number that looks wrong?